Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) EBITDA Margin (2019 - 2023)

Benitec Biopharma (BNTC) has disclosed EBITDA Margin for 5 consecutive years, with 66257.14% as the latest value for Q2 2023.

  • Quarterly EBITDA Margin changed N/A to 66257.14% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 309628.57% through Mar 2024, down 28122416.0% year-over-year, with the annual reading at 25529.33% for FY2023, 87454.0% down from the prior year.
  • EBITDA Margin hit 66257.14% in Q2 2023 for Benitec Biopharma, down from 8059.26% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6157.14% in Q2 2020 to a low of 393300.0% in Q1 2021.
  • Historically, EBITDA Margin has averaged 80603.12% across 5 years, with a median of 10725.0% in 2020.
  • Biggest five-year swings in EBITDA Margin: crashed -38257500bps in 2021 and later surged 38599167bps in 2022.
  • Year by year, EBITDA Margin stood at 2277.92% in 2019, then crashed by -13263bps to 304400.0% in 2020, then skyrocketed by 94bps to 19512.0% in 2021, then plummeted by -104bps to 39792.86% in 2022, then crashed by -67bps to 66257.14% in 2023.
  • Business Quant data shows EBITDA Margin for BNTC at 66257.14% in Q2 2023, 8059.26% in Q1 2023, and 39792.86% in Q4 2022.